Immunologic Approaches to Acute Leukemia in the Elderly

Seminars in Hematology

Volumn 43, Issue 2, 2006, Pages 118-125

  Farag, Sherif S ^a   Caligiuri, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALICHEAMICIN; CD16 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HISTAMINE; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 2; LINTUZUMAB; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; AGING; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL ACTIVITY; BLOOD TOXICITY; BOLUS INJECTION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELL FUNCTION; CELL INTERACTION; CLINICAL TRIAL; CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TOLERABILITY; GRAFT REJECTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INHIBITION KINETICS; LEUKEMIA CELL; LOW DRUG DOSE; LYMPHOKINE ACTIVATED KILLER CELL; METABOLIC DISORDER; MISMATCH NEGATIVITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TREATMENT RESPONSE;

ACUTE DISEASE; AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CYTOKINES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA;

EID: 33646008840     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.01.006     Document Type: Article

References (84)

1. Taylor P.R., Reid M.M., and Proctor S.J. Acute lymphoblastic leukaemia in the elderly. Leuk Lymphoma 13 (1994) 373-380
2. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (1994) 896-903
3. Stone R.M., Berg D.T., George S.L., Dodge R.K., Paciucci P.A., Schulman P.P., et al. Postremission therapy in older patients with de novo acute myeloid leukemia. A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98 (2001) 548-553
4. Pagano L., Mele L., Casorelli I., Fianchi L., Di Febo A., and Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica 85 (2000) 1327-1329
5. Bertz H., Potthoff K., and Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21 (2003) 1480-1484
6. Alyea E.P., Kim H.T., Ho V., Cutler C., Gribben J., DeAngelo D.J., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
7. Landay A.L., Zarcone D., Grossi C.E., and Bauer K. Relationship between target cell cycle and susceptibility to natural killer lysis. Cancer Res 47 (1987) 2767-2770
8. Allavena P., Damia G., Colombo T., Maggioni D., D'Incalci M., and Mantovani A. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol 120 (1989) 250-258
9. Trinchieri G. Biology of natural killer cells. Adv Immunol 47 (1989) 187-376
10. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., et al. Human natural killer cells. A unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 (2001) 3146-3151
11. Caligiuri M.A., Zmuidzinas A., Manley T.J., Levine H., Smith K.A., and Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171 (1990) 1509-1526
12. Baume D.M., Robertson M.J., Levine H., Manley T.J., Schow P.W., and Ritz J. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol 22 (1992) 1-6
13. Caligiuri M.A., Murray C., Robertson M.J., Wang E., Cochran K., Cameron C., et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin. Invest 91 (1993) 123-132
14. Nagler A., Lanier L.L., and Phillips J.H. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med 171 (1990) 1527-1533
15. Robertson M.J., Soiffer R.J., Wolf S.F., Manley T.J., Donahue C., Young D., et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF). Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 175 (1992) 779-788
16. + hematopoietic progenitor cells. Blood 87 (1996) 2632-2640
17. Fehniger T.A., and Caligiuri M.A. Interleukin 15. Biology and relevance to human disease. Blood 97 (2001) 14-32
18. Freud A.G., Becknell B., Roychowdhury S., Mao H.C., Ferketich A.K., Nuovo G.J., et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22 (2005) 295-304
19. Shimizu Y., and DeMars R. Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur J Immunol 19 (1989) 447-451
20. Lanier L.L. Activating and inhibitory NK cell receptors. Adv Exp Med Biol 452 (1998) 13-18
21. Lopez-Botet M., Bellon T., Llano M., Navarro F., Garcia P., and de Miguel M. Paired inhibitory and triggering NK cell receptors for HLA class I molecules. Hum Immunol 61 (2000) 7-17
22. Lopez-Botet M., Llano M., Navarro F., and Bellon T. NK cell recognition of non-classical HLA class I molecules. Semin Immunol 12 (2000) 109-119
23. Ljunggren H.G., and Karre K. In search of the 'missing self'. MHC molecules and NK cell recognition. Immunol Today 11 (1990) 237-244
24. Zijlstra M., Auchincloss Jr. H., Loring J.M., Chase C.M., Russell P.S., and Jaenisch R. Skin graft rejection by beta 2-microglobulin-deficient mice. J Exp Med 175 (1992) 885-893
25. + natural killer (NK) cells by the expression of clonally distributed functional surface molecules. Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 172 (1990) 1589-1598
26. Malnati M.S., Lusso P., Ciccone E., Moretta A., Moretta L., and Long E.O. Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements. J Exp Med 178 (1993) 961-969
27. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998) 795-799
28. Pende D., Parolini S., Pessino A., Sivori S., Augugliaro R., Morelli L., et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190 (1999) 1505-1516
29. Cantoni C., Bottino C., Vitale M., Pessino A., Augugliaro R., Malaspina A., et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 189 (1999) 787-796
30. Pessino A., Sivori S., Bottino C., Malaspina A., Morelli L., Moretta L., et al. Molecular cloning of NKp46. A novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188 (1998) 953-960
31. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
32. Bahram S. MIC genes. From genetics to biology. Adv Immunol 76 (2000) 1-60
33. Sutherland C.L., Chalupny N.J., Schooley K., VandenBos T., Kubin M., and Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 168 (2002) 671-679
34. Pende D., Cantoni C., Rivera P., Vitale M., Castriconi R., Marcenaro S., et al. Role of NKG2D in tumor cell lysis mediated by human NK cells. Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31 (2001) 1076-1086
35. Groh V., Rhinehart R., Randolph-Habecker J., Topp M.S., Riddell S.R., and Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2 (2001) 255-260
36. Farag S.S., George S.L., Lee E.J., Baer M., Dodge R.K., Becknell B., et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia. Cancer and Leukemia Group B study 9420. Clin Cancer Res 8 (2002) 2812-2819
37. Middleton D., Curran M., and Maxwell L. Natural killer cells and their receptors. Transplant Immunol 10 (2002) 147-164
38. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., and Caligiuri M.A. Natural killer cell receptors. New biology and insights into the graft-versus-leukemia effect. Blood 100 (2002) 1935-1947
39. Maraninchi D., Vey N., Viens P., Stoppa A.M., Archimbaud E., Attal M., et al. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk Lymphoma 31 (1998) 343-349
40. Meloni G., Foa R., Vignetti M., Guarini A., Fenu S., Tosti S., et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84 (1994) 2158-2163
41. Meloni G., Vignetti M., Andrizzi C., Capria S., Foa R., and Mandelli F. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease. updated experience with 20 cases. Leuk Lymphoma 21 (1996) 429-435
42. Olive D., Chambost H., Sainty D., Stoppa A.M., Blaise D., el Marsafy S., et al. Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2. Leukemia 8 (1994) 1230-1235
43. Lim S.H., Newland A.C., Kelsey S., Bell A., Offerman E., Rist C., et al. Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia-A phase II study. Cancer Immunol Immunother 34 (1992) 337-342
44. Meloni G., Vignetti M., Pogliani E., Ivernizzi R., Allione B., Mirto S., et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 3 (1997) S43-S47
45. Bergmann L., Heil G., Kolbe K., Lengfelder E., Puzicha E., Martin H., et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 16 (1995) 271-279
46. Wiernik P.H., Dutcher J.P., Todd M., Caliendo G., and Benson L. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 47 (1994) 41-44
47. Sievers E.L., Lange B.J., Sondel P.M., Krailo M.D., Gan J., Liu-Mares W., et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia. A report from the Children's Cancer Group. J Clin Oncol 16 (1998) 914-919
48. Fefer A., Benyunes M., Higuchi C., York A., Massumoto C., Lindgren C., et al. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Haematol 89 (1993) 2-7
49. Benyunes M.C., Massumoto C., York A., Higuchi C.M., Buckner C.D., Thompson J.A., et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12 (1993) 159-163
50. Massumoto C., Benyunes M.C., Sale G., Beauchamp M., York A., Thompson J.A., et al. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 17 (1996) 351-356
51. Robinson N., Benyunes M.C., Thompson J.A., York A., Petersdorf S., Press O., et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancy. A phase I/II study. Bone Marrow Transplant 19 (1997) 435-442
52. Meehan K.R., Badros A., Frankel S.R., Cahill R., Areman E., Jenson M., et al. A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies. J Hematother 6 (1997) 457-464
53. Benyunes M.C., Higuchi C., York A., Lindgren C., Thompson J.A., Buckner C.D., et al. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma. A feasibility trial. Bone Marrow Transplant 16 (1995) 283-288
54. Caligiuri M.A., Murray C., Soiffer R.J., Klumpp T.R., Seiden M., Cochran K., et al. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer. Prolonged immunomodulation without significant toxicity. J Clin Oncol 9 (1991) 2110-2119
55. Bernstein Z.P., Porter M.M., Gould M., Lipman B., Bluman E.M., Stewart C.C., et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86 (1995) 3287-3294
56. Bernstein Z.P., Khatri V., and Poiesz B. Phase I/II study of daily subcutaneous (sc) low dose interleukin-2 (IL-2) in AIDS-associated lymphomas (AIDS-NHL). Blood 92 (1998) 625a (abstr)
57. Fehniger T.A., Bluman E.M., Porter M.M., et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 106 (2000) 117-124
58. Farag S.S., George S.L., Lee E.J., Mrozek E., Cooper M.A., VanDeusen J.B., et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia. Cancer and Leukemia Group B study 9420. Clin Cancer Res 8 (2002) 2812-2819
59. Cortes J.E., Kantarjian H.M., O'Brien S., Giles F., Keating M.J., Freireich E.J., et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 85 (1999) 1506-1513
60. Ganser A., Heil G., Seipelt G., Hofmann W., Fischer J.T., Langer W., et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). Ann Hematol 79 (2000) 30-35
61. Blaise D., Attal M., Reiffers J., Michallet M., Bellanger C., Pico J.L., et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Network 11 (2000) 91-98
62. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., and Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258 (1992) 1795-1798
63. Kono K., Salazar-Onfray F., Petersson M., Hansson J., Masucci G., Wasserman K., et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 26 (1996) 1308-1313
64. Hansson M., Asea A., Ersson U., Hermodsson S., and Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 156 (1996) 42-47
65. Hansson M., Hermodsson S., Brune M., Mellqvist U.H., Naredi P., Betten A., et al. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res 19 (1999) 1135-1144
66. Johansson S., Landstrom M., Hellstrand K., and Henriksson R. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br J Cancer 77 (1998) 1213-1219
67. Hellstrand K., Naredi P., Lindner P., Lundholm K., Rudenstam C.M., Hermodsson S., et al. Histamine in immunotherapy of advanced melanoma. A pilot study. Cancer Immunol Immunother 39 (1994) 416-419
68. Agarwala S.S., Glaspy J., O'Day S.J., Mitchell M., Gutheil J., Whitman E., et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20 (2002) 125-133
69. Brune M., Castaigne S., Catalano J., Kurt G., Wolf-Karsten H., Anthony H., et al. Improved leukemia-free survival after post-consolidation treatment with histamine hydrochloride and interleukin-1 in AML. A randomized phase III trial. Blood 104 (2004) 261 (abstr)
70. Handgretinger R., Lang P., Schumm M., Pfeiffer M., Gottschling S., Demirdelen B., et al. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci 938 (2001) 340-357
71. Wetzler M., Baer M.R., Stewart S.J., Donohue K., Ford L., Stewart C.C., et al. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 15 (2001) 128-133
72. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
73. Kono K., Takahashi A., Ichihara F., Sugai H., Fujii H., and Matsumoto Y. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62 (2002) 5813-5817
74. Costello R.T., Sivori S., Marcenaro E., Lafage-Pochitaloff M., Mozziconacci M.J., Reviron D., et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99 (2002) 3661-3667
75. Dabholkar M., Tatake R., Amin K., Advani S., and Gangal S. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission. Oncology 46 (1989) 123-127
76. Carson W.E., Parihar R., Lindemann M.J., Personeni N., Dierksheide J., Meropol N.J., et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 31 (2001) 3016-3025
77. Friedberg J.W., Neuberg D., Gribben J.G., Fisher D.C., Canning C., Koval M., et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 117 (2002) 828-834
78. Caron P.C., Co M.S., Bull M.K., Avdalovic N.M., Queen C., and Scheinberg D.A. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 52 (1992) 6761-6767
79. Linenberger M.L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia. Progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19 (2005) 176-182
80. Feldman E.J., Brandwein J., Stone R., Kalaycio M., Moore J., O'Connor J., et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23 (2005) 4110-4116
81. Kossman S.E., Scheinberg D.A., Jurcic J.G., Jimenez J., and Caron P.C. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. Clin Cancer Res 5 (1999) 2748-2755
82. Koh C.Y., Blazar B.R., George T., Welniak L.A., Capitini C.M., Raziuddin A., et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97 (2001) 3132-3137
83. Ruggeri L., Capanni M., Casucci M., Volpi I., Tosti A., Perruccio K., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
84. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105 (2005) 3051-3057